Form 4: Centessa Pharmaceuticals Chief Business Officer Executes Options and Sells Shares Under Pre-Arranged Plan

Centessa Pharmaceuticals plc's Chief Business Officer, Gregory M. Weinhoff, exercised stock options and subsequently sold a portion of his shares on June 25, 2025, as part of a Rule 10b5-1 trading plan.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc (CNTA), reported transactions on June 25, 2025.
• He acquired 10,000 Ordinary Shares by exercising stock options at a price of $3.85 per share.
• Concurrently, he disposed of 10,000 Ordinary Shares at a weighted average price of $13.8642 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Weinhoff on May 22, 2024.
• The selling price ranged from $13.60 to $14.06 per share.
• Following these transactions, Mr. Weinhoff's direct beneficial ownership of Ordinary Shares decreased from 132,279 to 122,279.
• He retains 65,000 unexercised share options.
• The Ordinary Shares may be represented by American Depositary Shares (ADS), with each ADS currently representing one Ordinary Share.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which is a common practice for executives to manage their equity compensation and personal finances without implying a lack of confidence in the company.

Positives

• The Chief Business Officer successfully exercised options at a significantly lower price ($3.85) and sold shares at a much higher market price (weighted average $13.8642), indicating a profitable transaction for the insider.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a structured approach to managing personal holdings and reduces concerns about opportunistic insider trading.

Negatives

• The sale of shares by a Chief Business Officer, even under a pre-arranged plan, could be perceived by some investors as a lack of conviction in the company's near-term stock price appreciation, although it is often for personal financial planning or diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2024.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.

Stakeholder Impact

• Shareholders: May observe the Chief Business Officer's sale of shares, which could lead to varied interpretations regarding management's confidence or personal financial planning.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Chief Business Officer, Share Sale, Equity Compensation